Chemical Properties:
Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement. Storage Condition: Keep the container tightly closed and store in a cool, dry and well-ventilated warehouse away from incompatible substances. Protect from light and moisture. Shipping: Deliver to worldwide by air, by FedEx / DHL Express. Provide fast and reliable delivery.| Item | Specifications |
| Appearance | Off-White to Yellow Powder |
| Purity / Analysis Method | >95.0% (HPLC) |
| Moisture (K.F) | <1.00% |
| Residue on ignition | <0.50% |
| Impurity A | <3.00% (5-Acetyl-8-(Benzyloxy)quinolin-2(1H)-one) |
| Any Other Single Impurity | <1.50% |
| Total Impurities | <5.00% |
| Infrared Spectrum | Conforms to Structure |
| Test Standard | Enterprise Standard |
| Usage | Indacaterol Maleate (CAS: 753498-25-8) Intermediate |
Intermediates of Indacaterol Maleate:
Specifications:
Package & Storage:
| Chemical Name | 8-Benzyloxy-5-(2-Bromoacetyl)-2-Hydroxyquinoline |
| Synonyms | 8-(Benzyloxy)-5-(2-Bromoacetyl)quinolin-2(1H)-one; 5-(Bromoacetyl)-8-(Phenylmethoxy)-2(1H)-Quinolinone; 5-(2-Bromo-1-Oxoethyl)-8-Benzyloxy-2(1H)-Quinolinone; 5-Bromoacetyl-8-Benzyloxycarbostyril |
| CAS Number | 100331-89-3 |
| Stock Status | In Stock, Production Scale Up to Hundreds of Kilograms |
| Molecular Formula | C18H14BrNO3 |
| Molecular Weight | 372.21 |
| Melting Point | 192.0~194.0℃ |
| Boiling Point | 602.6±55.0℃ at 760 mmHg |
| Density | 1.479±0.06 g/cm3 |
| Brand | Ruifu Chemical |
Advantages:
FAQ:
100331-89-3 - Application:
Shanghai Ruifu Chemical Co., Ltd. is the leading manufacturer and supplier of 8-Benzyloxy-5-(2-Bromoacetyl)-2-Hydroxyquinoline (CAS: 100331-89-3) with high quality, it is an intermediate typically in the synthesis of Indacaterol Maleate (CAS: 753498-25-8). Indacaterol Maleate (CAS: 753498-25-8) is a new, ultra-long-acting, rapid onset β(2)-adrenoceptor agonist and bronchodilator. It is used in the treatment of chronic obstructive pulmonary disease (COPD) and asthma. The European Medicines Agency (EMA) approved indacaterol as a drug in 2009 under the Onbrez trade name while in the United States the Food and Drug Administration approved it under the trade name Arcapta in 2011. The drug is manufactured as its maleate salt form. Also, indacaterol is a chiral molecule; however, only the pure R-enantiomer is distributed.
